Obstructive sleep apnea (OSA) is a disorder characterized by repeated episodes of upper airway narrowing or closure during sleep despite ongoing respiratory effort. Events can cause oxygen desaturation, hemodynamic changes, and arousals that fragment sleep. Its cardiovascular relevance primarily includes relationships with hypertension, atrial fibrillation, ischemia, heart failure, and cerebrovascular risk, with important differences between clinical phenotypes.
Event frequency is summarized by the apnea–hypopnea index (AHI), but disease severity is not fully captured by this number. Symptoms, hypoxic burden, duration of disturbances, comorbidities, and functional consequences help distinguish people with different needs. Snoring is common but insufficient for diagnosis; the absence of obvious sleepiness does not exclude clinically significant sleep-disordered breathing.
The epidemiological association with cardiovascular events and the effect of treatment are separate questions. Observational associations may be affected by obesity, age, and other determinants; treatment that normalizes breathing has not necessarily been shown to reduce myocardial infarction or mortality in every population. Assessment must consider the strength of the mechanisms, documented clinical benefits, and limitations of outcome studies together.
During sleep, several mechanisms that keep the pharynx open become less active. Upper airway collapsibility depends on craniofacial anatomy, soft-tissue volume, adiposity, body position, and the function of dilator muscles. Retrognathia, enlargement of the tongue or tonsils, and neck characteristics may promote obstruction. Obesity is an important determinant, but OSA can also occur without an elevated BMI.
Anatomical predisposition interacts with nonanatomical mechanisms. An inadequate muscle response, low arousal threshold, and unstable ventilatory control can sustain repeated events. The concept of loop gain describes the magnitude of the ventilatory response to a disturbance: an excessive response can promote oscillations and instability. These mechanisms explain the disorder's heterogeneity, but not all are routinely measured in clinical practice.
The supine position and REM sleep can increase susceptibility in certain patients. Alcohol and sedative medications may impair muscle tone, the arousal threshold, or respiratory control; opioids add the risk of central events and hypoventilation. Age, sex, and hormonal changes contribute to susceptibility without independently establishing a diagnosis. Higher prevalence in men does not justify paying less attention to symptoms in women.
In heart failure and kidney disease, nocturnal fluid shifts from the limbs toward the chest and neck can increase pharyngeal tissue volume. The relationship with heart disease can therefore operate in both directions: disordered breathing worsens cardiovascular load, while congestion may promote disordered breathing. Management of fluid volume addresses a cardiac or renal need and may modify sleep without constituting a universal treatment for OSA.
Repeated falls and rebounds in oxygenation cause intermittent hypoxia and repeated activation of chemoreceptor pathways. Sympathetic activity, oxidative stress, and inflammatory signaling increase; endothelial dysfunction may reduce nitric oxide availability. The frequency, duration, and depth of episodes affect biological exposure, so two individuals with the same AHI may have different cardiovascular profiles.
Inspiratory efforts against a closed airway produce markedly negative intrathoracic pressures, altering ventricular loading and atrial wall stress. Left ventricular transmural afterload can increase, and fluctuations in venous return affect interactions between cardiac chambers. Arousals add autonomic surges and abrupt blood pressure changes; their nightly repetition acts on cardiac substrates with varying degrees of vulnerability.
Hypertension may be sustained by sympathetic activation and altered vascular regulation. Loss of the normal nocturnal blood pressure dip, nocturnal hypertension, and resistant forms are common. These patterns raise suspicion but do not in themselves establish OSA, because they also occur in other conditions. Blood pressure requires specific treatment while the contribution of sleep is investigated and addressed.
In atrial tissue, mechanical stress, inflammation, and autonomic changes may promote atrial fibrillation and a substrate for recurrence. Bradycardia, pauses, and other rhythm disturbances may also occur during events, followed by acceleration on arousal. A temporal association with sleep requires documentation and cardiological assessment; identifying apnea does not replace evaluation of embolic risk or independent indications for arrhythmia treatment.
OSA is associated with coronary and cerebrovascular disease through blood pressure, endothelial, metabolic, and thrombotic pathways. Ischemia may be facilitated by desaturation and increased cardiac demand, especially in coronary artery disease. However, the proportion of risk directly attributable to apnea varies by population and confounding factors; it is incorrect to convert every association into an individual causal percentage.
The relationship with heart failure includes increased cardiac loading, hypertension, and interactions with obesity and arrhythmias. Obstructive and central events may coexist in patients with heart disease and must be distinguished. Significant pulmonary hypertension should not automatically be attributed to isolated OSA: lung disease, hypoventilation, left-sided heart disease, and other causes must be considered, especially when hypoxemia is also present while awake.
Nocturnal symptoms include snoring and witnessed breathing pauses, awakenings with a choking sensation, restless sleep, and nocturia. Reports from a bed partner may be more informative than the patient's own perception, because episodes are not necessarily remembered. Isolated snoring is common and cannot reliably distinguish noisy breathing from a series of clinically significant obstructions.
During the day, sleepiness, fatigue, and headache, difficulty concentrating, irritability, and reduced productivity may emerge. Sleepiness and fatigue are not synonymous: the former denotes a tendency to fall asleep, while the latter describes perceived reduced energy. Insomnia or unrefreshing sleep may predominate; some patients with even severe disease report few symptoms and are identified because of a comorbidity.
History-taking covers sleep schedule and duration, shift work, alcohol, sedatives, opioids, weight changes, and previous treatments. Chronic sleep restriction may explain part of the sleepiness and coexist with OSA. Hypothyroidism, respiratory disease, neurological disorders, and psychiatric conditions enter the differential diagnosis when supported by the findings, avoiding automatic attribution of every symptom to apnea.
Suspicion is particularly relevant in resistant hypertension, atrial fibrillation, obesity, heart failure, or a history of cerebrovascular events. This supports targeted clinical assessment, but does not make the same test mandatory for every asymptomatic patient with heart disease. The choice considers likelihood, potential treatment benefits, and the impact of results on management.
Examination assesses adiposity and the upper airway, neck circumference, mandibular profile, oral cavity, tonsils, and nasal obstruction. Blood pressure, rhythm, and signs of congestion complete the cardiovascular assessment. Anatomy may suggest a mechanism but does not quantify sleep events; an apparently favorable examination does not exclude substantial nocturnal collapsibility.
Driving safety and safety in hazardous activities should be discussed when involuntary sleep episodes, near misses, or difficulty maintaining alertness are reported. Assessment does not depend solely on a scale score: actual history, sleep duration, medications, and the activity performed matter to the decision. Dangerous sleepiness requires prompt intervention and individualized safety advice without awaiting completion of a nonurgent cardiovascular evaluation.
Questionnaires such as STOP-Bang and Epworth help estimate the likelihood of OSA and subjective sleepiness, respectively, but do not establish the diagnosis. A high score requires interpretation and, when indicated, objective recording; a low score does not always rule out disease in minimally symptomatic phenotypes. Clinical assessment precedes testing and helps select the most appropriate method.
Polysomnography records sleep, airflow, respiratory effort, oxygenation, and other signals, enabling events to be related to sleep stages and arousals. Obstructive apnea involves a marked reduction in airflow, conventionally at least 90% for at least ten seconds in adults, with persistent effort. In a central event, respiratory effort is absent during the interruption of airflow; mixed events combine different components.
Hypopnea is identified by an airflow reduction of at least 30% for at least ten seconds, associated with desaturation or arousal according to the scoring rule used. The recommended AASM definition includes an oxygen saturation decrease of at least 3% or an arousal; other criteria require 4%. The report must identify the standard applied, because it may change the AHI and classification even though the patient has not changed.
The AHI expresses the number of apneas and hypopneas per hour of sleep. In adults, an index of at least 5 with relevant symptoms or clinical conditions can support the diagnosis, whereas at least 15 events per hour may meet the criterion even without reported symptoms. Conventional categories are mild from 5 to less than 15, moderate from 15 to less than 30, and severe from 30. These thresholds must not be transferred to pediatric patients and do not replace clinical assessment of severity.
Technically adequate home sleep apnea testing may be used in uncomplicated adults with a high likelihood of moderate or severe OSA. Many devices do not directly measure sleep: the respiratory event index is calculated using monitoring time and may underestimate events compared with a denominator consisting solely of hours asleep. Signal quality, sensor losses, and actual sleep duration must be considered before interpreting a negative result.
Significant cardiac or pulmonary disease, suspected hypoventilation, neuromuscular disease, chronic opioid use, previous stroke, or severe insomnia favors polysomnography according to AASM recommendations. If a home test is negative, inconclusive, or technically inadequate and suspicion persists, more comprehensive testing should follow. Even an initially negative polysomnographic study may warrant reassessment when the likelihood of disease and recording conditions do not align.
Overnight oximetry alone may reveal suggestive desaturations, but cannot always distinguish obstruction, central apnea, hypoventilation, and lung disease. Satisfactory mean saturation may conceal brief, repetitive episodes; prolonged low saturation may arise from mechanisms other than apnea. Wearable devices and consumer algorithms do not automatically replace validated clinical tests.
The report is interpreted together with the hypoxic burden and distribution of events, position, REM sleep, arousals, and symptoms. In the cohorts studied by Azarbarzin and colleagues, event-related hypoxic burden provided cardiovascular prognostic information beyond simple event counts. This is a biologically useful dimension but does not yet constitute a universal threshold that can replace all diagnostic and treatment criteria.
The differential diagnosis includes central apnea and hypoventilation. Obesity hypoventilation syndrome involves obesity and daytime hypercapnia, conventionally a PaCO₂ of at least 45 mmHg, after excluding other causes. When suspicion is not high, bicarbonate below 27 mmol/L may help exclude it; when suspicion is strong, arterial blood gas assessment is necessary. The mere coexistence of obesity and OSA does not establish hypoventilation.
Ambulatory 24-hour blood pressure monitoring can clarify nocturnal hypertension, absent physiological dipping, and apparent treatment resistance. Medication adherence, measurement technique, and other secondary causes are also checked. Recognition of OSA should not halt evaluation for hyperaldosteronism, kidney disease, or other determinants when clinical findings suggest them.
Palpitations, syncope, or suspected nocturnal arrhythmia may warrant ECG and prolonged monitoring. Echocardiography and other examinations are guided by signs of heart failure, valve disease, or other cardiac disorders, not prescribed indiscriminately for every elevated AHI. The indication for anticoagulation in atrial fibrillation remains based on risk and applicable recommendations, even when apnea is effectively treated.
Assessment of obesity and metabolic status completes the workup with anthropometric measurements, glucose, and lipids as appropriate. The relationship between adiposity and cardiovascular risk helps define shared goals, without assuming that weight loss corrects every anatomical abnormality. The respiratory response must be measured, especially before withdrawing effective treatment.
Goals include control of obstruction, improved alertness and sleep quality, safety, and comorbidity management. Choice depends on symptoms, severity, anatomy, hypoxemia, preferences, and the feasibility of sustained use. A patient with dangerous sleepiness needs different priorities from a minimally symptomatic person identified during cardiological screening, even if they have the same AHI.
Continuous positive airway pressure, or CPAP, keeps the airway open through pressure applied during sleep. When used correctly, it effectively reduces obstructive events and may improve sleepiness and quality of life. The auto-adjusting mode, APAP, varies pressure within defined limits and is an option in appropriate settings. Bilevel pressure is not automatically superior and is chosen for specific ventilatory or tolerance needs.
Initiation requires selecting the interface, checking leaks, explaining how the device works, and managing dryness, nasal congestion, or aerophagia. Humidification and gradual acclimatization may improve acceptance. Early follow-up is particularly important: a correctable problem with the mask should not lead to permanent abandonment. Telemonitoring and technical support are useful when linked to concrete clinical interventions.
Adherence is assessed through actual hours of use, regularity, and coverage of the sleep period, not simply by exceeding an administrative threshold. Using CPAP for four hours while sleeping eight leaves part of the night untreated, potentially including substantial REM sleep. The goal is use throughout sleep, adapted to the individual's course of care. Residual events, leaks, and persistent symptoms require review of settings and phenotype.
CPAP may help control blood pressure, particularly in people with resistant hypertension and consistent use. HIPARCO documented improvements in some 24-hour blood pressure measures and nocturnal patterns, without showing that the device replaces antihypertensive medication. The average effect is generally modest and variable; individual response should be assessed with appropriate measurements.
In the SAVE trial, adding CPAP to usual care in patients with moderate-to-severe OSA and established cardiovascular disease did not significantly reduce cardiovascular events in the intention-to-treat analysis. The population was largely not very sleepy, and mean use did not cover the entire night. Benefits in symptoms and quality of life were observed. The result limits any universal claim of event prevention but does not make treatment pointless for a symptomatic patient.
The 2023 individual participant data meta-analysis confirmed an overall neutral result for recurrent events in the randomized comparison, whereas the analysis of patients with at least four hours of use suggested a benefit. However, adherence was not randomly assigned and may reflect characteristics associated with a better prognosis, even after adjustment. The finding supports the importance of effective use and further research, without turning the association into a causal guarantee for every individual.
Also in atrial fibrillation, treating apnea is consistent with managing modifiable factors, but observational findings on recurrence are not equivalent to uniform demonstration in trials. Respiratory treatment is integrated with rate or rhythm control and stroke prevention. A good CPAP response does not automatically authorize discontinuation of anticoagulants or other cardiac treatments.
Weight loss may reduce collapsibility and events, with benefits varying by fat distribution and anatomy. Dietary changes, physical activity, and obesity treatment are tailored to capabilities and comorbidities. Improved weight alone does not prove OSA has resolved; symptoms and objective findings must be assessed before modifying respiratory support. Metabolic surgery may be appropriate for obesity according to its indications but requires surveillance for any residual apnea.
The two SURMOUNT-OSA trials assessed tirzepatide in adults with obesity and moderate-to-severe OSA, distinguishing people not using PAP from those using it. At 52 weeks, AHI, weight, and other measures, including hypoxic burden, improved. These findings support a role for pharmacological adiposity treatment in suitable patients, but the trials did not demonstrate reductions in myocardial infarction, stroke, or cardiovascular mortality. Indications, tolerability, and treatment continuity remain part of the decision.
Custom-fitted, adjustable mandibular advancement devices may be offered to selected patients, particularly when CPAP is not tolerated or an appropriate alternative is preferred. They require dental assessment, evaluation of the teeth and temporomandibular joint, and verification of respiratory effectiveness. Reduced snoring alone does not confirm control of apnea; occlusal changes and other effects require long-term monitoring.
Positional therapy is particularly useful when events are strongly dependent on the supine position and the event burden in other positions is limited. It is not equivalent to generically advising someone to “sleep on their side” without characterizing the phenotype. Adherence and respiratory control must be verified, and treatment may be combined with other measures when a single strategy is inadequate.
Upper airway surgery and hypoglossal nerve stimulation require specialist selection. Anatomy, collapse site, central components, severity, BMI, and prior treatment attempts influence indications; thresholds depend on the technique, device, and authorized pathway. Drug-induced sleep endoscopy and additional investigations may be required for planning, but do not replace diagnostic recording. Success is also measured after intervention, because improvement and cure are not synonymous.
Managing alcohol, sedatives, and nasal obstruction may improve breathing and treatment tolerance. Supplemental oxygen does not keep the pharynx open and is not a routine substitute for CPAP in isolated OSA; it may be necessary for other indications and requires particular caution if hypoventilation is present. Treating desaturation alone may leave respiratory effort, arousals, and obstruction unresolved.
For patients with central apnea or hypoventilation, ventilatory modes and goals require a separate pathway. OSA settings should not be transferred automatically, nor should advanced ventilation be selected without considering the type of cardiac disease and the safety of the mode. The presence of heart failure makes coordination among sleep medicine, pulmonology, and cardiology especially important.
Follow-up assesses symptoms, device use, residual events, weight, blood pressure, and associated conditions. Persistent sleepiness does not always mean insufficient pressure: inadequate sleep duration, medications, depression, other sleep disorders, and adherence problems should be considered. Major weight changes, new comorbidities, or an unexpected response may justify another recording. A device-estimated AHI must be interpreted alongside signals and the clinical situation.
Prognosis depends on phenotype and disease burden, not merely on the event count. Marked hypoxia, hypertension, obesity, cardiac disease, and duration of exposure may increase risk. Weight loss or control of respiratory events modifies some determinants, but preventing atherosclerosis and heart failure also requires managing lipids, blood pressure, diabetes, and smoking according to their respective indications.
Complications include impaired alertness and accidents, reduced quality of life, and cognitive or functional difficulties. Perioperative risks related to sedation, opioids, and obstruction are also relevant, and the team must be aware of the diagnosis and usual treatment. OSA severity is not expressed solely through cardiovascular events and may justify treatment because of immediate functional benefits.
From a cardiovascular perspective, hypertension and arrhythmias require ongoing attention, together with ischemic or heart failure symptoms. Available evidence does not support promising that CPAP will eliminate the risk of myocardial infarction or stroke, but does support individualized treatment of apnea and the problems it helps sustain. Improvement is documented through relevant respiratory, symptomatic, and clinical outcomes, with the goals and limitations of each treatment kept explicit.
Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.
Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.